'Treatment effect' diaporamas de présentation

Clinical Trial Designs for First-line Hormonal Treatment of Metastatic Breast Cancer

Clinical Trial Designs for First-line Hormonal Treatment of Metastatic Breast Cancer. Susan Honig, M.D. Patricia Cortazar, M.D. Rajeshwari Sridhara, Ph.D. John Johnson Alison Martin Grant Williams Julie Beitz Richard Pazdur. Gang Chen George Chi Ning Li Dianne Spillman Ann Staten.

830 views • 59 slides

PHARM

Placebo in Hypertension Adverse Reaction Meta-analysis PHARM A Collaborative Effort Effort Between: The Division of Cardio-Renal Drug Products IREF (Ischemia Research and Education Foundation) And Stephen Glasser Principals at FDA Albert DeFelice Jim Willard James Hung John Lawrence

984 views • 39 slides

Prospective Subset Analysis in Therapeutic Vaccine Studies

Prospective Subset Analysis in Therapeutic Vaccine Studies. Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://linus.nci.nih.gov/brb. Not.

593 views • 39 slides

Sex Offender-Specific Treatment Outcome Research: Learning Objectives

Sex Offender-Specific Treatment Outcome Research: Learning Objectives. Describe the general findings of sex offender-specific treatment outcome research Describe the financial costs and benefits of sex offender-specific treatment. Does Treatment Reduce Recidivism in Sex Offenders?.

586 views • 37 slides

Statistics 542 Introduction to Clinical Trials Meta Analysis

Statistics 542 Introduction to Clinical Trials Meta Analysis. Meta-Analysis. Alternatives? Occasionally Complementary? Yes Meta-Analysis Combination of similar studies using similar subjects and similar treatments and similar outcomes.

676 views • 32 slides

Treatment Switching in the VenUS IV trial

Treatment Switching in the VenUS IV trial. Methods to manage treatment non-compliance in RCTs with time-to-event outcomes. Caroline Fairhurst York Trials Unit. Context. Two arm RCT Clinical setting Continuous treatment Time-to-event outcome (e.g., death, healing). Dream or reality?.

614 views • 26 slides

Topics

Statistical Adaptation to Oncology Drug Development Evolution: From Cut/Burn/Poison to Immunotherapy Mingxiu Hu, PhD, ASA Fellow Sr. Vice President, Data Science and Systems Adjunct Professor of Biostatistics , Yale University 3 rd OncoStat Symposium, April 26-27, 2019. Topics.

689 views • 25 slides

Observational Studies

Observational Studies. Based on Rosenbaum (2002) David Madigan. Rosenbaum, P.R. (2002). Observational Studies (2 nd edition) . Springer. Introduction. A empirical study in which: Examples: smoking and heart disease vitamin C and cancer survival DES and vaginal cancer.

502 views • 25 slides

Bayesian Approach For Clinical Trials Mark Chang, Ph.D. Executive Director Biostatistics and Data management AMAG Pharm

Bayesian Approach For Clinical Trials Mark Chang, Ph.D. Executive Director Biostatistics and Data management AMAG Pharmaceuticals Inc. Mark.Chang@Statisticians.org MBC August 28, 2008, Boston, USA. Outlines. Basics of Bayesian Approach Frequentist Power versus Bayesian Power

626 views • 25 slides

HAT Trial

HAT Trial. Results of the Home Automated External Defibrillator Trial (HAT). HAT Trial. HAT Trial. Presented at ACC 2008 in Chicago Presented by Dr. Gust H. Bardy. Copyleft Clinical Trial Results. You Must Redistribute Slides. HAT Trial: Background.

475 views • 24 slides

Chapter 9: Introduction to the t statistic

Chapter 9: Introduction to the t statistic. The t Statistic. The t statistic allows researchers to use sample data to test hypotheses about an unknown population mean.

717 views • 23 slides

Econometric Approaches to Causal Inference: Difference-in-Differences and Instrumental Variables

Econometric Approaches to Causal Inference: Difference-in-Differences and Instrumental Variables. Graduate Methods Master Class Department of Government, Harvard University February 25, 2005. Overview: diff-in-diffs and IV. Data Randomized experiment Observational data

946 views • 21 slides

Acorn Strategies

Acorn Strategies. How Acorn Size Influences Seedling Size and Possible Choices. Acorns Sized by Round Hole Screens . Four nurseries in Study Wilson, JP : Red oak only Valonia, Penn : Red and white oak Made as many sizes as possible with round hole screens

418 views • 21 slides

Difference in Difference Models

505 views • 20 slides

Long-Term Outcome of a Routine versus Selective Invasive Strategy in Patients with non-ST elevation ACS

Long-Term Outcome of a Routine versus Selective Invasive Strategy in Patients with non-ST elevation ACS . Keith AA Fox, Tim C Clayton, Peter Damman, Stuart J Pocock, Robbert J de Winter, Jan GP Tijssen, Bo Lagerqvist, Lars Wallentin. FIR collaboration: F RISC I CTUS R ITA.

306 views • 20 slides

Disclosure Statement of Financial Interest

Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME 2 trial.

407 views • 20 slides

Species diversity: rarefaction, evenness and indices

Species diversity: rarefaction, evenness and indices. Problem 1: Accounting for sample size. Are these two communities equally diverse?. Problem 2: Accounting for abundance. Are these two communities equally diverse?. Resampling techniques.

462 views • 18 slides

Lipid Disorders and Management in Diabetes

Lipid Disorders and Management in Diabetes. Om P. Ganda MD Joslin Diabetes Center Harvard Medical school Boston, MA. Web-conference, April 8, 2010. MRFIT: Cholesterol and CVD Mortality in Men With Type 2 Diabetes. Age-Adjusted CVD deaths per 10,000 person-years. ?280.

450 views • 18 slides

Fenofibrate Intervention and Event Lowering in Diabetes

FIELD. Fenofibrate Intervention and Event Lowering in Diabetes. Presented at The American Heart Association Scientific Sessions, November 2005 Presented by Dr. Anthony Keech. FIELD: Background.

294 views • 10 slides

Sub - Sampling

Sub - Sampling. It may be necessary or convenient to measure a treatment response on subsamples of a plot several soil cores within a plot duplicate laboratory analyses to estimate grain protein Introduces a complication into the analysis that can be handled in one of two ways:

696 views • 10 slides